HHS-HRSA Terminates 340B Drug Pricing Program Registration Waiver
Highlights
The HHS-HRSA issued a notice terminating its 340B Program registration waiver for hospitals’ offsite, outpatient facilities
The agency is providing hospital entities time to comply with the registration requirements, provided certain notice requirements are met
Failure to comply with the notice and registration requirements or stop purchasing 340B Program drugs for use at these facilities could result in removal of the hospital from the program and/or refunds of discounts to drug manufacturers
A group of health systems from across the country is seeking to block the HHS-HRSA in court from reinstating the registration requirements
The Health Resources and Services Administration of the U.S. Department of Health and Human Services (HHS-HRSA) issued a notice to safety net hospitals on Oct. 27 that ends the 340B offsite, outpatient hospital facility registration waiver that went into effect during the COVID-19 pandemic.
Keep Up to Date in a Changing World
